AssetMark’s Bicycle Therapeutics BCYC Stock Holding History
Bought
Maintained
Sold
Other funds holding BCYC
NCNMGF
AssetMark's BCYC Position: Q3 2026 in Review
AssetMark sold out of Bicycle Therapeutics (BCYC) in Q3 2026, closing a stake of 1,588 shares — an estimated $6.73K sold.
AssetMark first reported a position in BCYC in Q3 2024 and held it in 8 quarters. The position peaked at $34.4K in Q3 2024. 61 funds tracked by Wall St. Rank hold BCYC as of Q3 2026.
- AssetMark reported no remaining Bicycle Therapeutics position as of Q3 2026 after selling out during the quarter.
- AssetMark sold 1,588 Bicycle Therapeutics shares in Q3 2026, an estimated $6.73K.
- AssetMark first reported a position in Bicycle Therapeutics in Q3 2024 and held it in 8 quarters.
- AssetMark's Bicycle Therapeutics position peaked at $34.4K in Q3 2024.
- 61 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.